[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][=C][Branch2][Ring2][Branch2][C][=Branch1][C][=O][C][=C][Branch1][Branch1][C][Ring1][#Branch1][=O][N][C][C@H1][C@@H1][Branch2][Ring1][C][C@@][Ring1][Branch1][Branch1][O][C@@H1][Ring1][#Branch2][C][O][C][=Branch1][C][=O][N][O][C][N][Ring1][N][N]"}, {"from": "gpt", "value": "The molecule is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies.  Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to ab externo glaucoma surgeries."}]